Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Onco360 Oncology Pharmacy

Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Revuforj® (revumenib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360® Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra® (tislelizumab-jsgr)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant®, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for VORANIGO® (vorasidenib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy for crovalimab-akkz
From Onco360 Oncology Pharmacy
Via GlobeNewswire
CORRECTION -- Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360® Celebrates Excellent Patient Care, Reflected by Impressive Net Promoter Score
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)
From Onco360 Oncology Pharmacy
Via Business Wire
FABHALTA (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
From Onco360 Oncology Pharmacy
Via Business Wire
OGSIVEO™ (nirogacestat) Now Available from Onco360 as the First and Only FDA-Approved Treatment for Adults with Progressing Desmoid Tumors Who Require Systemic Treatment
From Onco360 Oncology Pharmacy
Via Business Wire
TRUQAP™ (capivasertib) Now Available from Onco360
From Onco360 Oncology Pharmacy
Via Business Wire
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
From Onco360 Oncology Pharmacy
Via Business Wire
AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360
From Onco360 Oncology Pharmacy
Via Business Wire
OJJAARA™ (momelotinib) Now Available from Onco360 For the Treatment of Intermediate or High-Risk Myelofibrosis (MF), Including Primary MF or Secondary MF [Post-Polycythemia Vera (PV) and Post- Essential Thrombocythemia (ET)], in Adults with Anemia
From Onco360 Oncology Pharmacy
Via Business Wire
ELREXFIO™ (elranatamab-bcmm), Now Available from Onco360
From Onco360 Oncology Pharmacy
Via Business Wire
VANFLYTA® (quizartinib) Now Available from Onco360
From Onco360 Oncology Pharmacy
Via Business Wire
Lytgobi® (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements
From Onco360 Oncology Pharmacy
Via Business Wire
ORSERDU™ Now Available from Onco360 for the Treatment of Postmenopausal Women or Adult Men, with ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer with Disease Progression Following at Least One Line of Endocrine Therapy
From Onco360 Oncology Pharmacy
Via Business Wire
JAYPIRCA™ (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor
From Onco360 Oncology Pharmacy
Via Business Wire
TIBSOVO® (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-mutant Acute Myeloid Leukemia or Previously Treated, IDH1-mutant Metastatic Cholangiocarcinoma
From Onco360 Oncology Pharmacy
Via Business Wire
LUMAKRAS™ (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
From Onco360 Oncology Pharmacy
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.